Boston, United States
Rectify Pharma is a burgeoning player in the biotechnology sector, established with a focus on developing Positive Functional Modulators (PFMs)—a pioneering class of oral, small molecules designed to restore and enhance membrane protein function. The company targets the root causes of serious diseases through their innovative approach, particularly excelling in the realms of liver, cardio-renal-metabolic, and neurodegenerative disorders.
Founded in 2020 in the United States, Rectify Pharma leverages its platform to accelerate the discovery of potentially first- and best-in-class therapeutic candidates, addressing both rare and prevalent diseases. The startup's early journey was significantly bolstered by a substantial $100M Series A investment on 14 October 2021. This funding was spearheaded by Atlas Venture and Omega Funds, with participation from Forbion and Longwood Fund, underscoring a strong vote of confidence from leading investors in the life sciences domain.
